<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393689</url>
  </required_header>
  <id_info>
    <org_study_id>PCT2017-1</org_study_id>
    <secondary_id>2017-002604-27</secondary_id>
    <nct_id>NCT03393689</nct_id>
  </id_info>
  <brief_title>RGD PET/MRI in Sporadic Vestibular Schwannoma</brief_title>
  <official_title>Kan tumorvækst Forudsiges Ved RGD-PET/MR af Vestibularis Schwannomer?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this non-randomised, prospective study is to investigate the applicability and
      prognostic value of angiogenesis PET/MR with the radioligand 68Ga-NODAGA- E[c(RGDyK)]2 in
      patients with sporadic Vestibuarl Schwannomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The radioligand 68Ga-NODAGA- E[c(RGDyK)]2 targets the Arg-Gly-Asp (RGD) sequence known to
      bind with the αvβ3 integrin that is expressed on the surface of angiogenic blood vessels or
      tumor cells. The radioligand can be used to visualize tumor angiogenesis using PET/MR.

      A total of 40 patients diagnosed with sporadic vestibular schwannomas will be subjected to an
      angiogenesis-PET/MR scan. Follow-up MR-only scan will be performed (from the time of the
      angiogenesis PET/MR) minimum 2 months later in regards to calculate growth rate. The uptake
      of 68Ga-NODAGA-E[c(RGDyK)]2 (Standardized Uptake Values, SUVmax) in tumor lesions will be
      quantified as Standardized Uptake Values (SUVmax/SUVmean) and compared with PFS, DSS and OS
      (dichotomized above/below median SUVmax and analyzed by Kaplan-Meier).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">January 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiogenesis PET/MR imaging of patients with sporadic Vestibular Schwannomas</measure>
    <time_frame>1 hour</time_frame>
    <description>The radioligand 68Ga-NODAGA-E[c(RGDyK)]2 can be used as a prognostic marker for growth rate in patients with sporadic vestibular schwannomas.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acoustic Neuroma</condition>
  <arm_group>
    <arm_group_label>Angiogenesis PET/MR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/MR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>One injection of 68Ga-NODAGA-E[c(RGDyK)]2</intervention_name>
    <description>One injection of 68Ga-NODAGA-E[c(RGDyK)]2</description>
    <arm_group_label>Angiogenesis PET/MR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 18 years with MRI verified sporadic vestibular schwannomas

          -  Patients &gt; 18 år whom max has been in watchful waiting regime in 12 months and/or max.
             received 1 follow-up MRI scan.

          -  Must be able to read and understand the patient information in Danish and to give
             informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Breast-feeding

          -  Weight more than the maximum weight limit for the PET/MR bed of the scanner (140 kg)

          -  History of allergic reaction attributable to compounds of similar chemical or biologic
             composition to 68Ga-NODAGA-E[c(RGDyK)]2

          -  Recent systemic treatment with steroids

          -  Hormone treatment incl. birth control pills.

          -  Claustrofobia

          -  Non-MRI compatible implants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hjalte C.R. Sass, MD, Ph.d.-Fellow</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hjalte C.R. Sass, MD, Phd-fellow</last_name>
    <phone>+45 31310730</phone>
    <email>hjalte.christian.reeberg.sass.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Kjær, DMSci, Phd, Professor</last_name>
    <phone>+45 51724829</phone>
    <email>andreas.kjaer@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Otolaryngology, Head and Neck Surgery &amp; Audiology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hjalte C.R. Sass, MD, Ph.d.-fellow</last_name>
      <phone>+45 31310730</phone>
      <email>hjalte.christian.reeberg.sass.01@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Per Cayé-Thomasen, DMSci, Professor</last_name>
      <phone>+45 35452075</phone>
      <email>per.caye-thomasen.01@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Hjalte C.R. Sass, MD, Ph.d.-fellow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Hjalte Sass</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>68Ga-NODAGA-E[c(RGDyK)]2</keyword>
  <keyword>Angiogenesis PET/MR</keyword>
  <keyword>Acoustic Neuroma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroma</mesh_term>
    <mesh_term>Neuroma, Acoustic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

